Mounjaro Cost: What You May Pay and Why It Varies

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

You are reading this inside the PlexusDx Education Hub, where we unpack GLP-1 therapies, weight-management protocols, and the inherited biology that colors each of those choices. Browse the full Peptides & GLP-1 library.

The most useful way to understand Mounjaro cost is not a single number but a set of scenarios, because what you pay depends heavily on which situation you are in. This page starts from the published list price, then walks through three realistic out-of-pocket situations and the factors that separate them. Everything reflects published information as of April 2026 and is offered as context, not a quote.

The published starting point

Mounjaro’s U.S. list price is roughly $1,069 per month as of April 2026, per Eli Lilly’s published pricing. That number precedes insurance, rebates, manufacturer cards, and pharmacy negotiation, and it is rarely what an insured patient actually pays. Every scenario below moves away from it in a different direction.

Scenario one: covered indication with a savings card

When a commercial plan covers the prescribed indication and an eligible patient applies the manufacturer savings card, monthly cost can drop to as little as $25, depending on the plan’s terms and the card’s caps. This is the lowest-cost path, and it requires both an approved indication and card eligibility.

Scenario two: commercial plan, uncovered indication

If the plan does not cover the indication on the prescription, cash-pay cost typically lands closer to list price minus whatever coupon applies. Independent platforms such as GoodRx and SingleCare publish discount prices that vary by pharmacy and can soften that figure.

Scenario three: no insurance

Without any coverage, out-of-pocket cost approaches the full list price. Here, compounded alternatives through licensed pathways and pharmacy discount cards become the main levers people reach for, though availability and pricing vary.

What decides which scenario is yours

Coverage hinges on the FDA-approved indication written on the script and the plan’s formulary and prior-authorization rules. Type 2 diabetes coverage is common; chronic weight management is more variable, frequently BMI-gated, and sometimes excluded. Medicare does not cover weight-management indications for weight alone as of April 2026. Confirm your own plan’s stance directly.

Where compounded options sit

During the FDA-declared shortages, licensed 503A pharmacies compounded semaglutide and tirzepatide legally. The semaglutide shortage resolved in late 2024 and the tirzepatide shortage in early 2025, narrowing but not eliminating legitimate compounding. Compounded products are not identical to the brand and carry separate pricing, including through the PlexusDx Weight Management Protocols.

The biology behind the budget

Before running the scenarios, PlexusDx looks at the metabolism itself. The Precision Peptide Genetic Test analyzes 14 pathways, 49 peptides, 150+ genetic insights, including variants in FTO, and MC4R that shape baseline appetite and energy balance. It does not predict response to any medication. PlexusDx offers semaglutide and tirzepatide, including Tirzepatide Injection, within those protocols.

Finding your own scenario

The fastest way to use these three situations is to work out which one describes you before you shop. Check whether your plan covers the written indication, then whether you qualify for the manufacturer card. Those two answers place you in the lowest-cost, middle, or cash-pay lane almost immediately.

Why the lanes shift

None of these scenarios is fixed. Formularies change, savings-card caps reset, and coupon prices move by pharmacy and over time, so a person can slide from one lane to another as their coverage or prescription changes. Re-checking where you land whenever your plan, indication, or dose changes keeps your expectations aligned with reality, and keeps the conversation with your provider anchored in your current situation rather than an old one. A renewal at the start of a plan year is a particularly common moment for a lane to shift, since formularies and card terms are often reset then, and a price that held steady for months can move without warning. Building a brief check into that renewal window spares you the surprise of discovering the change at the pharmacy counter.

Frequently Asked Questions

What is the lowest I might pay?

With a covered indication and an applied manufacturer savings card, eligible commercially-insured patients may pay as little as $25 per month, subject to plan terms and card caps. That lowest-cost figure requires both an approved indication and card eligibility — not everyone qualifies for both.

What if my plan does not cover the indication?

Cash-pay cost typically moves toward the roughly $1,069 list price as of April 2026, minus any coupon. Independent discount platforms like GoodRx and SingleCare may reduce that, with prices varying by pharmacy. Compounded alternatives through licensed pathways are priced separately.

Does Medicare help with the cost?

Medicare does not cover weight-management indications for weight alone as of April 2026, though cardiovascular-indication coverage exists for some products. Because coverage depends on the specific indication and plan, the reliable answer comes from checking your own Medicare plan directly.

How does the genetic test fit a cost decision?

It sits upstream of it. The Precision Peptide Genetic Test never predicts drug response or lowers price. It analyzes pathway-level variants such as FTO and MC4R to give metabolic context before you commit — a test-before-you-invest step to bring into your provider conversation.

Keep exploring the rest of the collection in the PlexusDx Education Hub.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.